• MAHAMMAD RAHMATHULLA SB 1Department of Biochemistry, Sri Krishnadevaraya University, Anantapuramu, India2Department of Biochemistry, College of Medicine and Health Sciences, Gondar (Ethiopia).


Cardiovascular disease (CVD) is the most frequent cause of premature death in modern industrialized countries, accounting for 4.35 million deaths each year in Europe, and 35% of deaths in the United Kingdom. Atherosclerosis is pathological process characterized by formation of subintimal plaques that can reduce or obstruct blood flow through the vessel. It is a result of normal blood vessels ageing, with initial lesion developing before age 30 (so-called fatty streaks). Risk factors that significantly accelerate this process are serum lipid impairment, hypertension, cigarette smoking, diabetes mellitus, obesity, physical inactivity and hereditary factors i.e. positive family history of cardiovascular disorders. . Compelling experimental and clinical evidence has demonstrated that both systemic and local inflammation might play a prominent role in the pathogenesis of atherosclerosis and its clinical complications. Since inflammatory processes accompany all stages of atherosclerosis, measurement of plasma/serum concentrations of circulating inflammatory biomarkers might aid in identifying individuals at high risk for cardiovascular disease (CVD). Currently employed treatment strategies include risk factor modification, conventional pharmacotherapy, and percutaneous or surgical revascularization. Yet despite these interventions disease progression often results in recurrent symptoms, with many patients exhausting all therapeutic options.

KEY WORDS: Atherosclerosis, Risk Factors, Pathophysiology, Inflammation. Biomarkers for Atherosclerosis, Polyphenols, Molecular and Cell Based Therapies

Author Biography

MAHAMMAD RAHMATHULLA SB, 1Department of Biochemistry, Sri Krishnadevaraya University, Anantapuramu, India2Department of Biochemistry, College of Medicine and Health Sciences, Gondar (Ethiopia).

Working as a Assistant professorin Biochemistry, for ~ 4 years at Gondar Medical College and Health Sciences ,ETHIOPIA


1. Hamoud S, Hayek T, Volkova N, Attias J, Moscoviz D, Rosenblat M, et al. Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study. Atherosclerosis 2014;232(1):204-10.
2. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004;25(14):1197-207.
3. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004;13(3):125-38.
4. Santos-Gallego CG, Ibanez B, Badimon JJ. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol 2008;76(4):443-52.
5. Rahmathulla SB, Lakshmi Devi K. Practical Biochemistry Manual (Methods and Interpretations). Vol. 25. ???: LAP Lambert Academic Publishing; 2013. p. 65-8.
6. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95(3):594-9.
7. Kannel Wb, Dawber Tr, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease – six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50.
8. Milei J, Ottaviani G, Lavezzi AM, Grana DR, Stella I, Matturri L. Perinatal and infant early atherosclerotic coronary lesions. Can J Cardiol 2008;24(2):137-41.
9. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20(5):1262-75.
10. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1994;14(5):840-56.
11. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1992;12(1):120-34.
12. Rahamathulla SB, Sailaja KV, Shivaranjani VL, Poornima H, Lakshmi Devi K. Protective effect of Tribulus terrestris L. fruit aqueous extract on lipid profile and oxidative stress in isoproterenol induced myocardial necrosis in male albino wistar rats. EXCLI J 2013;12:373-83.
13. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15(9):1512-31.
14. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326(4):242-50.
15. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103:934-40.
16. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92(5):1355-74.
17. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottish men with 21 years of follow up. BMJ 1999;318(7200):1725-9.
18. Hansagi H, Romelsjö A, Gerhardsson de Verdier M, Andréasson S, Leifman A. Alcohol consumption and stroke mortality 20-year follow-up of 15,077 men and women. Stroke 1995;26(10):1768-73.
19. Kauhanen J, Kaplan GA, Goldberg DE, Salonen R, Salonen JT. Pattern of alcohol drinking and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1999;19(12):3001-6.
20. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976;193(4258):1094-100.
21. Libby P. Inflammation in atherosclerosis. Nature 2002;420(6917):868-74.
22. Majdalawieh A, Zhang L, Fuki IV, Rader DJ, Ro HS. Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. Proc Natl Acad Sci U S A 2006;103(7):2346-51.
23. Pöykkö SM, Kellokoski E, Ukkola O, Kauma H, Päivänsalo M, Kesäniemi YA, et al. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 2006;260(1):43-52.
24. Mahammad SB, Sailaja KV, Kodidhela LD. Tribulus terrestris (l) protects heart and liver from beta adrenergic-stimulated cardiotoxicity: Biochemical and histological study in wistar rats. Int J Drug Dev Res 2013;5(1):264-70.
25. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70 3 Suppl:491S-9.
26. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339(8808):1523-6.
27. Dubick MA, Omaye ST. Evidence for grape, wine and tea polyphenols as modulators of atherosclerosis and ischemic heart disease in humans. J Nutr Funct Med Foods 2001;3:67-93.
28. Nardini M, Natella F, Scaccini C. Role of dietary polyphenols in platelet aggregation. A review of the supplementation studies. Platelets 2007;18(3):224-43.
29. Vita JA. Polyphenols and cardiovascular disease: Effects on endothelial and platelet function. Am J Clin Nutr 2005;81 1 Suppl:292S-7.
30. Maeda K, Kuzuya M, Cheng XW, Asai T, Kanda S, Tamaya-Mori N, et al. Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier. Atherosclerosis 2003;166(1):23-30.
31. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001;154(6):495-503.
32. Gupta AK, Misra N. Hepatoprotective activity of aqueous ethanolic extract of chamomile capitula in paracetamol intoxicated albino rats. Am J Pharmcol Toxicol 2006;1(1):17-20.
33. Mahammad Rahmathulla SB, Maruthi E, Bheemewsaraiah K, Manjunatha S, Lakshmi Devi K. Effect of Tribulus terrestris (L.) on liver in isoproterenol-induced myocardial infarction. Int J Res Biochem Biophys 2012;2(4):10-2.
34. Mahammad Rahmathulla SB. Effect of Tribulus terrestris fruit aqueous extract on hyperlipidaemia and maintenance of liver architecture in isoproterenol-induced myocardial infarction in rats. Int J Pharm Bio Sci 2013;4(1):983-92.
35. Khachigian LM. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 2000;106(10):1189-95.
36. Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 2001;92(1):19-25.
37. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003;92(4):436-9.
38. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999;230(4):466-70.
39. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100(5):468-74.
40. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105(17):2012-8.
41. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivelä A. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of post angioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107(21):2677-83.
42. Sugano M, Makino N. Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J Biol Chem 1996;271(32):19080-3.43. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998;273(9):5033-6.
44. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 1995;92(10):4502-6.
45. Suzuki J, Isobe M, Morishita R, Aoki M, Horie S, Okubo Y, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997;3(8):900-3.
46. Suzuki J, Isobe M, Morishita R, Nishikawa T, Amano J, Kaneda Y. Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res 2000;45(3):783-7.
47. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: Results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002;39(2):281-7.
48. Jain M, DerSimonian H, Brenner DA, Ngoy S, Teller P, Edge AS, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001;103(14):1920-7.
49. Saito T, Kuang JQ, Lin CC, Chiu RC. Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction. J Thorac Cardiovasc Surg 2003;126(1):114-23.
50. Bel A, Messas E, Agbulut O, Richard P, Samuel JL, Bruneval P, et al. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation 2003;108 Suppl 1:II247-52.
51. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9(6):702-12.
52. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003;107(24):3093-100.
53. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348(7):593-600.
54. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89(1):E1-7.
55. Goldschmidt-Clermont PJ. Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis. Am Heart J 2003;146:S5-12.
56. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002;360(9331):427-35.
57. Gough PJ, Raines EW. Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood 2003;101(2):485-91.
58. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91(4):281-91.
59. Nicoletti A, Caligiuri G, Hansson GK. Immunomodulation of atherosclerosis: myth and reality. J Intern Med 2000;247(3):397-405.
60. Hansson GK. Vaccination against atherosclerosis: Science or fiction? Circulation 2002;106(13):1599-601.
61. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21(12):1876-90.
62. Richter MH, Richter H, Barten M, Schramm D, Weinert M, Gummert J, et al. Cyclosporin A does not enhance the development of transplant vasculopathy: experimental study in a rat cardiac transplant model. Transplant Proc 2002;34(5):1479-80.
63. Chen W, Thoburn CJ, Miura Y, Sommer M, Hruban R, Qian Z, et al. Autoimmune-mediated vasculopathy. Clin Immunol 2001;100(1):57-70.
64. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998;97(3):242-4.
65. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20(11):2394-400.
66. Wu R, Shoenfeld Y, Sherer Y, Patnaik M, Matsuura E, Gilburd B, et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations – possible immunomodulation of atherosclerosis. Autoimmunity 2003;36(2):91-7.
351 Views | 537 Downloads
How to Cite
SB, M. R., and L. D. K. “ADVANCED MOLECULAR AND CELL BASED THERAPIES FOR ATHEROSCLEROSIS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 1, Jan. 2015, pp. 54-59,
Review Article(s)